Plasma exchange in France: Epidemiology 2001

被引:31
作者
Korach, JM [1 ]
Petitpas, D [1 ]
Paris, B [1 ]
Bourgeade, F [1 ]
Passerat, V [1 ]
Berger, P [1 ]
Chillet, P [1 ]
机构
[1] Gen Hosp, Intens Care Unit, F-51000 Chalons Sur Marne, France
关键词
D O I
10.1016/S1473-0502(03)00120-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The French plasma exchange registry created in 1985 lists the indications, techniques and complications of the French therapeutic haemapheresis. In 2001 it contains the data of more than 16,700 patients for a total of 153,641 sessions. The indications concern five groups of pathologies (neurology, haematology, nephrology, vasculitis, and endocrinology). Until 2000, the neurology represented the most important group but the use of the high dose IgIV for Guillain-Barre and myasthenia gravis decreased the indications. The haematology became most important group treated because of the increase of the TTP and HUS number treated. The endocrinology (familial hypercholesterolemia) represents at present 10% of the patients treated for 18.7% of the sessions. The vascular access little changed since 1985, the peripheral venous access being the most used. The plasma substitution initially based on the albumin alone was gradually replaced by an association albumin macromolecules, in particular hydroxyethyl starch since 1990. After the observation of the side effects due to starches we observed an increase of the albumin alone use. The immediate complications decreased in half in 15 years. The French plasma exchange registry is the largest world database of haemapheresis with the cooperation of about 80 centres, allowing numerous scientific studies. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码:153 / 157
页数:5
相关论文
共 12 条
[1]   Hydroxyethylstarch as a risk factor for acute renal failure - Is a change of clinical practise indicated? [J].
Boldt, J .
DRUG SAFETY, 2002, 25 (12) :837-846
[2]   Effect of hydroxyethylstarch in brain-dead kidney donors on renal function in kidney-transplant recipients [J].
Cittanova, ML ;
Leblanc, I ;
Legendre, C ;
Mouquet, C ;
Riou, B ;
Coriat, P .
LANCET, 1996, 348 (9042) :1620-1622
[3]  
Clark W F, 1991, J Clin Apher, V6, P40, DOI 10.1002/jca.2920060109
[4]   Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis [J].
Gajdos, P ;
Chevret, S ;
Clair, B ;
Tranchant, C ;
Chastang, C .
ANNALS OF NEUROLOGY, 1997, 41 (06) :789-796
[5]   Plasma exchange and intravenous immunoglobulin in autoimmune myasthenia gravis [J].
Gajdos, P ;
Chevret, S ;
Clair, B ;
Tranchant, C ;
Chastang, C .
MYASTHENIA GRAVIS AND RELATED DISEASES: DISORDERS OF THE NEUROMUSCULAR JUNCTION, 1998, 841 :720-726
[6]  
Guillevin L, 1997, ANN MED INTERNE, V148, P198
[7]   Role of replacement fluids in the immediate complications of plasma exchange [J].
Korach, JM ;
Berger, P ;
Giraud, C ;
Le Perff-Desman, C ;
Chillet, P .
INTENSIVE CARE MEDICINE, 1998, 24 (05) :452-458
[8]  
Raphael JC, 1996, PRESSE MED, V25, P1516
[9]  
RAPHAEL JC, 1993, ANN MED INTERNE, V144, P526
[10]  
Sefrin P, 1998, Anaesthesiol Reanim, V23, P149